- Home
- OMCL vs VRDN Comparison
OMCL vs VRDN Comparison
Compare OMCL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCL
- VRDN
- Stock Information
- Founded
- OMCL 1992
- VRDN 2006
- Country
- OMCL United States
- VRDN United States
- Employees
- OMCL N/A
- VRDN N/A
- Industry
- OMCL Computer Manufacturing
- VRDN Medical Specialities
- Sector
- OMCL Technology
- VRDN Health Care
- Exchange
- OMCL Nasdaq
- VRDN Nasdaq
- Market Cap
- OMCL 1.6B
- VRDN 1.6B
- IPO Year
- OMCL 2001
- VRDN N/A
- Fundamental
- Price
- OMCL $35.26
- VRDN $12.56
- Analyst Decision
- OMCL Buy
- VRDN Buy
- Analyst Count
- OMCL 6
- VRDN 12
- Target Price
- OMCL $51.00
- VRDN $36.44
- AVG Volume (30 Days)
- OMCL 637.0K
- VRDN 718.2K
- Earning Date
- OMCL 05-01-2025
- VRDN 05-07-2025
- Dividend Yield
- OMCL N/A
- VRDN N/A
- EPS Growth
- OMCL N/A
- VRDN N/A
- EPS
- OMCL 0.27
- VRDN N/A
- Revenue
- OMCL $1,112,238,000.00
- VRDN $302,000.00
- Revenue This Year
- OMCL $4.02
- VRDN N/A
- Revenue Next Year
- OMCL $4.32
- VRDN $17,629.40
- P/E Ratio
- OMCL $130.41
- VRDN N/A
- Revenue Growth
- OMCL N/A
- VRDN N/A
- 52 Week Low
- OMCL $25.12
- VRDN $11.40
- 52 Week High
- OMCL $55.75
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- OMCL 45.08
- VRDN 28.07
- Support Level
- OMCL $33.89
- VRDN $14.03
- Resistance Level
- OMCL $35.37
- VRDN $15.91
- Average True Range (ATR)
- OMCL 1.11
- VRDN 0.67
- MACD
- OMCL 0.38
- VRDN -0.19
- Stochastic Oscillator
- OMCL 81.20
- VRDN 0.71
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.